How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

295 results for

adhd Bupropion

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Efficacy Of Bupropion For Attention Deficit Hyperactivity Disorder (ADHD) In Adults

, 2011 Results First Posted: February 25, 2011 Last Update Posted: March 8, 2013 Last Verified: March 2013 Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Substance-Related Disorders Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Chemically-Induced Disorders Bupropion (...) Efficacy Of Bupropion For Attention Deficit Hyperactivity Disorder (ADHD) In Adults Efficacy Of Bupropion For Attention Deficit Hyperactivity Disorder (ADHD) In Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2011 Clinical Trials

22. Bupropion

. But if you still have questions please contact us via jon.brassey@tripdatabase.com Top results for bupropion 1. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is a prevalent neurobiological condition, characterised by behavioral and cognitive symptoms such as inattention, impulsivity and/or excessive activity. The syndrome is commonly accompanied by psychiatric comorbidities and is associated with educational (...) and occupational underachievement.Although psychostimulant medications are the mainstay of treatment for ADHD (...) , not all adults respond optimally to, or can tolerate, these medicines. Thus, alternative non-stimulant treatment approaches for ADHD have been explored. One of these alternatives is bupropion , an aminoketone antidepressant and non-competitive antagonism of nicotinic acetylcholine receptors. Bupropion is registered for the treatment of depression and smoking cessation, but is also used off

2018 Trip Latest and Greatest

23. ADHD

examination by a physician/medical doctor - Psychological 2016 10. Bupropion for attention deficit hyperactivity disorder ( ADHD ) in adults. BACKGROUND: Attention deficit hyperactivity disorder ( ADHD ) is a prevalent neurobiological condition, characterised by behavioral and cognitive symptoms such as inattention, impulsivity and/or excessive activity. The syndrome is commonly accompanied by psychiatric comorbidities and is associated with educational and occupational underachievement.Although (...) the effects and safety of bupropion for the treatment of adults 2017 11. Attention deficit hyperactivity disorder ( ADHD ) in children and adolescents 2017 12. Methylphenidate for attention deficit hyperactivity disorder ( ADHD ) in children and adolescents - assessment of adverse events in non-randomised studies. BACKGROUND: Attention deficit hyperactivity disorder ( ADHD ) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication

2018 Trip Latest and Greatest

24. Attention-deficit hyperactivity disorder management Full Text available with Trip Pro

. healthlinks.net Pty. Ltd. Archived from (PDF) on 21 July 2008 . Retrieved 2 July 2008 . ^ Kumar, R (2008). "Approved and investigational uses of modafinil : an evidence-based review". Drugs . 68 (13): 1803–39. : . . ^ Linton, D; Barr, AM; Honer, WG; Procyshyn, RM (May 2013). "Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability". Current Psychiatry Reports . 15 (5): 355. : . . Loy, JH (...) as "non-stimulant". (Strattera) Atomoxetine is less effective than stimulants for ADHD, is associated with rare cases of liver damage, : 5 and carries a U.S. FDA regarding suicidal ideation. Controlled studies show increases in heart rate, decreases of body weight, decreased appetite and treatment-emergent nausea. (Intuniv) The extended release form has been approved by the FDA for the treatment of attention-deficit hyperactivity disorder (ADHD) in children as an alternative to stimulant medications

2012 Wikipedia

25. Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review

Crescenzo , Samuele Cortese , , Nicoletta Adamo , Luigi Janiri Statistics from Altmetric.com Introduction Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neuropsychiatric conditions, with a pooled worldwide prevalence estimated at about 5% in school-aged children and persistence of impairing symptoms in adulthood in up to 65% of cases. The pooled estimated prevalence of ADHD (as categorical diagnosis) in adults is around 2.5%. ADHD is characterised by a persistent and impairing (...) value of combining pharmacological and non-pharmacological treatments. References Faraone SV , Asherson P , Banaschewski T , et al . Attention-deficit/hyperactivity disorder . Moffitt TE , Houts R , Asherson P , et al . Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study . Seixas M , Weiss M , Muller U . Systematic review of national and international guidelines on attention-deficit hyperactivity disorder . Thapar A , Cooper M

2017 Evidence-Based Mental Health

26. Medication for ADHD: what works for adults, adolescents and children

there was considerable and when a Cochrane review by Storebø et al (2015) questioned the efficacy and tolerability of methylphenidate in children and adolescents with ADHD. In light of controversies such as these, the robust evidence provided by Cortese et al. (2018) ‘ Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis ’ is an important step forward in understanding ADHD (...) Medication for ADHD: what works for adults, adolescents and children Medication for ADHD: what works for adults, adolescents and children Search National Elf Service Search National Elf Service » » » » Medication for ADHD: what works for adults, adolescents and children Jan 10 2019 Posted by is a neurodevelopmental disorder characterised by impairing and age-inappropriate levels of inattention, impulsivity or hyperactivity, or a combination of these (American Psychiatric Association, 2013

2019 The Mental Elf

27. High Dose Bupropion for Smoking Cessation

: mean score of items, range = 1-5, higher scores = more social anxiety 29 Item Inventory of Depressive and Anxious Symptomology - traumatic intrusions subscale [ Time Frame: baseline session, 4, 8, 16, 26 weeks post quite date ] traumatic intrusions subscale: mean score of items, range = 1-5, higher scores = more traumatic intrusions 18- item adult self report scale for Attention deficit/Hyperactivity disorder (ADHD) [ Time Frame: baseline session, 4, 8, 16, 26 weeks post quite date ] ADHD symptom (...) High Dose Bupropion for Smoking Cessation High Dose Bupropion for Smoking Cessation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. High Dose Bupropion for Smoking Cessation The safety and scientific

2017 Clinical Trials

28. Bupropion

malformation overall, cardiac malformation overall, intrauterine death, low birth weight or preterm delivery following maternal bupropion use in pregnancy. Although single case-control studies have suggested possible associations with specific cardiac malformations including coarctation of the aorta and ventricular septal defects, these observations have not been replicated in other studies. One study has provided evidence that bupropion may be associated with an increased risk of ADHD in the offspring (...) of women who were treated with bupropion for depression. However, this finding was based on a small number of exposed infants with ADHD resulting in an imprecise risk estimate which may have been confounded by the underlying maternal condition. This observation therefore requires confirmation in further studies. Due to the limited efficacy and pregnancy safety data, bupropion is not routinely recommended as a smoking cessation aid for pregnant women. However, each patient needs to be assessed on a case

2014 UK Teratology Information Service

29. CX717 in the Treatment of Adult ADHD

Product: No Product Manufactured in and Exported from the U.S.: No Keywords provided by RespireRx: ADHD, ampakine, Phase II clinical trial Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders (...) to Assess the Efficacy And Safety of the Ampakine® Compound, CX717, versus Placebo in Adults with Attention-Deficit Hyperactivity Disorder Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: CX717 200 mg Drug: CX717 800 mg Drug: Placebo Phase 2 Detailed Description: This study examined the clinical efficacy, tolerability and safety of CX717 in the treatment of adults with ADHD. The study was a double-blind, 2-period crossover study that compared 2 different

2017 Clinical Trials

30. Dasotraline Pediatric ADHD Study

with ADHD. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: Dasotraline Drug: Placebo Comparator Phase 2 Phase 3 Detailed Description: This is a randomized, double blind, multicenter, placebo-controlled, parallel group, outpatient study evaluating the efficacy and safety of dasotraline in subjects 6 to 12 years of age with ADHD using 2 doses of dasotraline (2 mg/day and 4 mg/day) versus placebo over a 6 week treatment period. The study will consist (...) Placebo in Subjects 6 to 12 Years of Age With Attention Deficit Hyperactivity Disorder (ADHD) Study Start Date : April 2015 Actual Primary Completion Date : July 2016 Actual Study Completion Date : July 2016 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Dasotraline 2 mg Dasotraline 2 mg Drug: Dasotraline Dasotraline 2 mg once daily Other Name: SEP-225289 Experimental: Dasotraline 4 mg Dasotraline 4 mg

2015 Clinical Trials

31. Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers

Disorder (OCD) and ADHD); Suicidal ideation (within the past 10 years) or lifetime occurrence of attempted suicide; Current depression; Bulimia or anorexia; Use of opiate medications for pain or sleep (non-opiate medication for pain or sleep will be allowed) within the past 14 days; Smoking more than one cigar a month. Alcohol abuse; Significant adverse reaction to nicotine patches, bupropion / Wellbutrin / Zyban or Chantix / varenicline in the past. Current participation or recent participation (...) : January 18, 2016 Last Verified: October 2015 Keywords provided by Duke University: Nicotine addiction Cigarette smoking Smoking cessation Zyban Chantix Nicotine patches varenicline bupropion Additional relevant MeSH terms: Layout table for MeSH terms Tobacco Use Disorder Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Nicotine Varenicline Bupropion Ganglionic Stimulants Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Nicotinic Agonists

2013 Clinical Trials

32. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK

Health Service. The methodology was valid, but most of the details of the methods and results were published in another paper. The authors’ conclusions appear to be robust. Type of economic evaluation Cost-utility analysis Study objective This study was an economic evaluation of atomoxetine for children with attention deficit and hyperactivity disorder (ADHD) compared with alternative treatments, such as psychostimulants, in various subgroups of patients depending on their previous treatment history (...) Cottrell S, Tilden D, Robinson P, et al. A modelled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value in Health 2008; 11(3): 376-388. Prasad S, Harpin V, Poole L. A multi-centre, randomised, open-label study of atomoxetine with standard current therapy in UK children and adolescents with ADHD. Current Medical Research and Opinion 2007; 23: 379-394. Indexing Status Subject indexing

2009 NHS Economic Evaluation Database.

33. Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers. Full Text available with Trip Pro

research has focused on cognitive processes, such as attention and working memory, which may predict relapse. In addition, there may also be sex differences in cognitive-related deficits during nicotine deprivation. The current sample consisted of 58 (22 females) daily smokers (at least 10 cigarettes per day) randomized to receive bupropion (300 mg/day), varenicline (2 mg/day), or placebo. After a 1-week run-up phase, participants completed a 9.5-hr laboratory session after overnight abstinence (CO (...) verified). Participants completed measures of attention (Conners' Continuous Performance Task [CPT]), working memory (digits backward), and delay discounting. Measures of craving, withdrawal, and mood were also collected. Between-subjects ANCOVA models revealed that varenicline speeded reaction time, but reduced accuracy on the CPT compared with placebo. Sex moderated the effect of bupropion compared with placebo on working memory and delay discounting. Bupropion enhanced working memory for females

2012 Experimental and clinical psychopharmacology Controlled trial quality: uncertain

34. Neuroimaging, Omega-3 and Reward in Adults With ADHD (NORAA) Trial

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute on Alcohol Abuse and Alcoholism (NIAAA) ): fMRI Reward Processing Nutrition Omega-3 Fatty Acids ADHD Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders (...) they received the omega-3 or placebo. Condition or disease Intervention/treatment Phase Attention Deficit Disorder Attention Deficit Hyerpactivity Disorder Other: Highly unsaturated omega-3 fatty acids Phase 2 Detailed Description: Objective: Both attention deficit hyperactivity disorder (ADHD) and addictive behaviors have been persistently related to impaired reward-related processes in the ventral striatum as evidenced by functional magnetic resonance imaging studies (fMRI). These impairments

2014 Clinical Trials

35. Open-label Safety Study in Adults With ADHD

Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms (...) of SEP 225289 in adult subjects with Attention Deficit Hyperactivity Disorder (ADHD) Condition or disease Intervention/treatment Phase Adult Attention Deficit Hyperactivity Disorder Drug: Dasotraline Phase 3 Detailed Description: To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with ADHD by the incidence of adverse events (AEs; or serious AEs), AEs (or SAEs) leading to discontinuation Study Design Go to Layout table for study information Study Type : Interventional

2014 Clinical Trials

36. Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity

, Canada: ADHD ADD Anxiety Anxiety Disorders Depression Attention Attention Deficit Additional relevant MeSH terms: Layout table for MeSH terms Disease Anxiety Disorders Depressive Disorder Depression Attention Deficit Disorder with Hyperactivity Pathologic Processes Mental Disorders Mood Disorders Behavioral Symptoms Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Lisdexamfetamine Dimesylate Central Nervous System Stimulants Physiological Effects of Drugs Dopamine (...) in the treatment of anxiety and depressive disorders which commonly occur with ADHD. To examine the potential relationship between telomere length and Adult ADHD with comorbidity and the potential effect of treatment response. To examine the potential associations with specific genes and Adult ADHD. Condition or disease Intervention/treatment Phase Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders Drug: Lisdexamfetamine Dimesylate Drug: placebo Phase 4

2013 Clinical Trials

37. Near Infrared Spectroscopy in Children With Autism and ADHD

different tasks. Researchers want to study children with attention deficit hyperactivity disorder (ADHD) and autism spectrum disorders (ASD) and will use NIRS to compare the blood flow in the brain of children with ADHD and ASD with that of typically developing children. Objectives: To see how well NIRS can detect changes in brain blood flow during tests of thinking and memory in children. To compare blood flow in the brains of typically developing children and those with ADHD or ASD. Eligibility (...) ) and Attention Deficit Hyperactivity Disorder (ADHD). Study population: Children with ASD, ADHD, and typically developing children, all between 4 and 8 years of age. Design: The study will investigate NIRS signal changes while children with ASD, ADHD, and typically developing children perform well-known functional tasks. Outcome Measures: Graded changes in blood flow and oxygen, measured with NIRS, in response to different functional tasks. Study Design Go to Layout table for study information Study Type

2012 Clinical Trials

38. Concurrent Bupropion / Varenicline for Smoking Cessation

: Nicoderm Drug: Nicotine Inhaler Nicotine inhaler to use as needed after quit date Other Name: Nicotrol Inhaler Active Comparator: varenicline with bupropion This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline in combination with bupropion. Drug: Varenicline For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date (...) fainting spells; Problems giving blood samples; Diabetes treated with insulin; non-insulin treated diabetes (unless glucose is less than 180mg/dcl and HbA1c is less than 7%); Current cancer or treatment for cancer in the past six months (except basal or squamous cell skin cancer); Other major medical condition; Current psychiatric disease (with the exception of anxiety disorders, obsessive compulsive disorder (OCD) and ADHD); Suicidal ideation (within the past 10 years) or lifetime occurrence

2011 Clinical Trials

39. Bupropion Full Text available with Trip Pro

the rewarding properties of nicotine, i.e., low doses augment nicotine self-administration and high doses attenuate it. In Australia and the UK, smoking cessation is the only licensed use of bupropion. In the US, the FDA granted approval for marketing of bupropion for depression and smoking cessation. Attention deficit hyperactivity disorder [ ] It is uncertain whether bupropion is safe or effective for treatment of in children. The 2007 guideline on the ADHD treatment from American Academy of Child (...) and tobacco use cessation agent". CNS Drug Rev . 12 (3–4): 178–207. : . . Research, Center for Drug Evaluation and. . www.fda.gov . Retrieved 14 March 2019 . Pliszka S (July 2007). "Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder". J Am Acad Child Adolesc Psychiatry . 46 (7): 894–921. : . . Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M (June 2006). "The Texas Children's

2012 Wikipedia

40. Chronic obstructive pulmonary disease in over 16s: diagnosis and management

antitrypsin deficiency, consider therapy and screen family Symptoms disproportionate to lung function deficit Look for other explanations including cardiac impairment, pulmonary hypertension, depression and hyperventilation Frequent infections Exclude bronchiectasis Haemoptysis Exclude carcinoma of the bronchus 1.1.31 People who are referred do not always have to be seen by a respiratory physician. In some cases they may be seen by members of the COPD team who have appropriate training and expertise (...) Smoking cessation 1.2.2 Document an up-to-date smoking history, including pack years smoked (number of cigarettes smoked per day, divided by 20, multiplied by the number of years smoked) for everyone with COPD. [2004] [2004] 1.2.3 At every opportunity, advise and encourage every person with COPD who is still smoking (regardless of their age) to stop, and offer them help to do so. [2004] [2004] 1.2.4 Unless contraindicated, offer nicotine replacement therapy, varenicline or bupropion as appropriate

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>